Oliver Langford
Overview
Explore the profile of Oliver Langford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Birkenbihl C, Cuppels M, Boyle R, Klinger H, Langford O, Coughlan G, et al.
Brain Inform
. 2025 Jan;
12(1):3.
PMID: 39871006
Cognitive resilience (CR) describes the phenomenon of individuals evading cognitive decline despite prominent Alzheimer's disease neuropathology. Operationalization and measurement of this latent construct is non-trivial as it cannot be directly...
2.
Birkenbihl C, Cuppels M, Boyle R, Klinger H, Langford O, Coughlan G, et al.
medRxiv
. 2024 Sep;
PMID: 39228697
Cognitive resilience describes the phenomenon of individuals evading cognitive decline despite prominent Alzheimer's disease neuropathology. Operationalization and measurement of this latent construct is non-trivial as it cannot be directly observed....
3.
Molina-Henry D, Raman R, Liu A, Langford O, Johnson K, Shum L, et al.
Alzheimers Dement
. 2024 Apr;
20(6):3827-3838.
PMID: 38629508
Introduction: In trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron...
4.
Rissman R, Langford O, Raman R, Donohue M, Abdel-Latif S, Meyer M, et al.
Alzheimers Dement
. 2023 Nov;
20(2):1214-1224.
PMID: 37932961
Introduction: Incorporating blood-based Alzheimer's disease biomarkers such as tau and amyloid beta (Aβ) into screening algorithms may improve screening efficiency. Methods: Plasma Aβ, phosphorylated tau (p-tau)181, and p-tau217 concentration levels...
5.
Winston C, Langford O, Levin N, Raman R, Yarasheski K, West T, et al.
J Alzheimers Dis
. 2023 Jan;
92(1):95-107.
PMID: 36710683
Background: Participant eligibility for the A4 Study was determined by amyloid PET imaging. Given the disadvantages of amyloid PET imaging in accessibility and cost, blood-based biomarkers may serve as a...
6.
Donohue M, Langford O, Insel P, van Dyck C, Petersen R, Craft S, et al.
Pharm Stat
. 2023 Jan;
22(3):508-519.
PMID: 36627206
Mixed model repeated measures (MMRM) is the most common analysis approach used in clinical trials for Alzheimer's disease and other progressive diseases measured with continuous outcomes over time. The model...
7.
Cai T, Abel L, Langford O, Monaghan G, Aronson J, Stevens R, et al.
BMJ
. 2021 Jul;
374:n1537.
PMID: 34261627
Objective: To assess the associations between statins and adverse events in primary prevention of cardiovascular disease and to examine how the associations vary by type and dosage of statins. Design:...
8.
Raman R, Quiroz Y, Langford O, Choi J, Ritchie M, Baumgartner M, et al.
JAMA Netw Open
. 2021 Jul;
4(7):e2114364.
PMID: 34228129
Importance: Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD) clinical trials limits generalizability of results and hinders opportunities to examine potential effect modification of candidate treatments. Objective: To examine...
9.
Sato K, Ihara R, Suzuki K, Niimi Y, Toda T, Jimenez-Maggiora G, et al.
Alzheimers Dement (N Y)
. 2021 Mar;
7(1):e12135.
PMID: 33778148
Background: Selecting cognitively normal elderly individuals with higher risk of brain amyloid deposition is critical to the success of prevention trials for Alzheimer's disease (AD). Methods: Based on the Anti-Amyloid...
10.
Marshall G, Sikkes S, Amariglio R, Gatchel J, Rentz D, Johnson K, et al.
Alzheimers Dement (Amst)
. 2020 Nov;
12(1):e12118.
PMID: 33163609
Introduction: We examined the associations among instrumental activities of daily living (IADL), cortical amyloid, and cognition in cognitively normal (CN) older adults. Methods: CN participants screening for the A4 Study...